• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒感染者住院后是否需要广泛使用抗生素?

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

机构信息

Infectious Diseases Department, Dijon University Hospital, Dijon, France.

Internal Medicine Department, Dijon University Hospital, Dijon, France; INSERM CIC 1432, Module Plurithématique, University of Burgundy, Dijon, France.

出版信息

Int J Infect Dis. 2021 Apr;105:256-260. doi: 10.1016/j.ijid.2021.01.051. Epub 2021 Jan 27.

DOI:10.1016/j.ijid.2021.01.051
PMID:33508478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7839401/
Abstract

BACKGROUND

Debate continues regarding the usefulness and benefits of wide prescription of antibiotics in patients hospitalized with coronavirus disease 2019 (COVID-19).

METHODS

All patients hospitalized in the Infectious Diseases Department, Dijon University Hospital, Dijon, France between 27 February and 30 April 2020 with confirmed COVID-19 were included in this study. Clinical, biological and radiological data were collected, as well as treatment and outcome data. An unfavourable outcome was defined as death or transfer to the intensive care unit. Patient characteristics and outcomes were compared between patients who did and did not receive antibiotic therapy using propensity score matching.

FINDINGS

Among the 222 patients included, 174 (78%) received antibiotic therapy. The univariate analysis showed that patients who received antibiotic therapy were significantly older, frailer and had more severe presentation at admission compared with patients who did not receive antibiotic therapy. Unfavourable outcomes were more common in patients who received antibiotic therapy [hazard ratio (HR) 2.94, 95% confidence interval (CI) 1.07-8.11; P = 0.04]. Multi-variate analysis and propensity score matching indicated that antibiotic therapy was not significantly associated with outcome (HR 1.612, 95% CI 0.562-4.629; P = 0.37).

CONCLUSION

Antibiotics were frequently prescribed in this study and this was associated with more severe presentation at admission. However, antibiotic therapy was not associated with outcome, even after adjustment. In line with recent publications, such data support the need to streamline antibiotic therapy in patients with COVID-19.

摘要

背景

对于在因 2019 年冠状病毒病(COVID-19)住院的患者中广泛开具抗生素的用处和益处,仍存在争议。

方法

本研究纳入了 2020 年 2 月 27 日至 4 月 30 日期间在法国第戎大学医院传染病科住院的所有确诊 COVID-19 的患者。收集了临床、生物学和放射学数据以及治疗和结局数据。不良结局定义为死亡或转入重症监护病房。使用倾向评分匹配比较接受和未接受抗生素治疗的患者的特征和结局。

结果

在纳入的 222 例患者中,174 例(78%)接受了抗生素治疗。单因素分析显示,与未接受抗生素治疗的患者相比,接受抗生素治疗的患者年龄更大、身体更虚弱,入院时病情更严重。接受抗生素治疗的患者不良结局更为常见[风险比(HR)2.94,95%置信区间(CI)1.07-8.11;P=0.04]。多变量分析和倾向评分匹配表明,抗生素治疗与结局无显著相关性(HR 1.612,95% CI 0.562-4.629;P=0.37)。

结论

在本研究中,抗生素经常被开具,这与入院时病情更严重有关。然而,即使在调整后,抗生素治疗与结局也无相关性。与最近的出版物一致,此类数据支持需要简化 COVID-19 患者的抗生素治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5942/7839401/83febd3dd960/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5942/7839401/83febd3dd960/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5942/7839401/83febd3dd960/gr1_lrg.jpg

相似文献

1
Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?新冠病毒感染者住院后是否需要广泛使用抗生素?
Int J Infect Dis. 2021 Apr;105:256-260. doi: 10.1016/j.ijid.2021.01.051. Epub 2021 Jan 27.
2
Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study.法国 COVID-19 住院患者的特征和结局:Critical COVID-19 France(CCF)研究。
Arch Cardiovasc Dis. 2021 May;114(5):352-363. doi: 10.1016/j.acvd.2021.01.003. Epub 2021 Mar 2.
3
Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80.80 岁以上住院 COVID-19 患者的死亡率风险和抗生素使用。
Biomed Pharmacother. 2022 Feb;146:112481. doi: 10.1016/j.biopha.2021.112481. Epub 2021 Dec 28.
4
Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids.抗生素治疗与全身用皮质类固醇治疗的哮喘加重住院患者结局的关联。
JAMA Intern Med. 2019 Mar 1;179(3):333-339. doi: 10.1001/jamainternmed.2018.5394.
5
Association Between Early Antibiotic Therapy and In-Hospital Mortality Among Older Patients With SARS-CoV-2 Pneumonia.早期抗生素治疗与老年 SARS-CoV-2 肺炎患者住院死亡率的关系。
J Gerontol A Biol Sci Med Sci. 2022 Apr 1;77(4):e115-e123. doi: 10.1093/gerona/glab209.
6
The effect of outpatient antibiotic treatment of coronavirus disease 2019 on the outcomes in the emergency department: a propensity score matching study.门诊抗生素治疗 2019 年冠状病毒病对急诊科结局的影响:倾向评分匹配研究。
Croat Med J. 2022 Feb 28;63(1):53-61. doi: 10.3325/cmj.2022.63.53.
7
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
8
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
9
Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort.糖尿病与 COVID-19 患者结局的相关性:来自法国回顾性队列的倾向评分匹配分析。
Diabetes Metab. 2021 Jul;47(4):101222. doi: 10.1016/j.diabet.2020.101222. Epub 2020 Dec 31.
10
Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study.抗凝治疗是 COVID-19 的潜在保护因素:一项法国多中心队列研究的启示
J Am Heart Assoc. 2021 Apr 20;10(8):e018624. doi: 10.1161/JAHA.120.018624. Epub 2021 Feb 8.

引用本文的文献

1
The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study.抗生素治疗对中度新冠肺炎住院患者临床结局的影响:一项前瞻性多中心队列研究。
Infection. 2025 Jun 26. doi: 10.1007/s15010-025-02590-0.
2
Does Empirical Antibiotic Use Improve Outcomes in Ventilated Patients with Pandemic Viral Infection? A Multicentre Retrospective Study.经验性使用抗生素能否改善大流行病毒感染通气患者的预后?一项多中心回顾性研究。
Antibiotics (Basel). 2025 Jun 8;14(6):594. doi: 10.3390/antibiotics14060594.
3
Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview.

本文引用的文献

1
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.COVID-19 住院患者合并感染和再感染的发生率:一项回顾性队列研究。
Clin Microbiol Infect. 2021 Jan;27(1):83-88. doi: 10.1016/j.cmi.2020.07.041. Epub 2020 Jul 31.
2
Pharmaco-Immunomodulatory Therapy in COVID-19.COVID-19 的药物免疫调节治疗。
Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z.
3
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
达巴万星在抗菌药物耐药时代治疗革兰氏阳性菌感染中的应用概述
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):1-4. doi: 10.33393/grhta.2024.3108. eCollection 2024 Jan-Dec.
4
Timing and prediction of secondary bacteremia in patients with COVID-19: A retrospective cohort study.2019冠状病毒病患者继发性菌血症的时间及预测:一项回顾性队列研究。
J Gen Fam Med. 2024 Apr 30;25(4):206-213. doi: 10.1002/jgf2.697. eCollection 2024 Jul.
5
The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks.新冠疫情后抗生素消费趋势:应对未来疫情的方法
Infect Drug Resist. 2024 Jun 4;17:2227-2236. doi: 10.2147/IDR.S460148. eCollection 2024.
6
The evolution of lung computed tomography findings in COVID-19 from 2020 to 2023: more signs of co-infection.2020年至2023年COVID-19患者肺部计算机断层扫描结果的演变:合并感染迹象增多。
ERJ Open Res. 2024 Feb 26;10(1). doi: 10.1183/23120541.00727-2023. eCollection 2024 Jan.
7
Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.抗菌药物管理前瞻性审核和反馈对 COVID-19 住院患者的疗效和安全性(COVASP):一项实用的、基于群组的、非劣效性试验。
Lancet Infect Dis. 2023 Jun;23(6):673-682. doi: 10.1016/S1473-3099(22)00832-5. Epub 2023 Jan 27.
8
Hospital Antibiotic Use during COVID-19 Pandemic in Italy.意大利新冠疫情期间医院抗生素的使用情况。
Antibiotics (Basel). 2023 Jan 13;12(1):168. doi: 10.3390/antibiotics12010168.
9
Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management.用于即时护理COVID-19监测的多重生物传感器:基于CRISPR的无扩增RNA诊断和基于蛋白质的治疗药物管理。
Mater Today (Kidlington). 2022 Dec;61:129-138. doi: 10.1016/j.mattod.2022.11.001. Epub 2022 Nov 9.
10
Antibiotic Prescription and In-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study.COVID-19患者的抗生素处方与院内死亡率:一项前瞻性多中心队列研究
J Pers Med. 2022 May 26;12(6):877. doi: 10.3390/jpm12060877.
新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
4
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴:目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
5
Cytokine Storms: Understanding COVID-19.细胞因子风暴:了解 COVID-19。
Immunity. 2020 Jul 14;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017. Epub 2020 Jun 28.
6
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎:意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
7
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.细菌和真菌合并感染冠状病毒的个体:一项支持 COVID-19 抗菌药物处方的快速综述。
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.
8
Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States.2019年冠状病毒病(COVID-19)住院患者的临床特征、实验室检查结果及预后:来自美国的早期报告
Diagnosis (Berl). 2020 May 26;7(2):91-96. doi: 10.1515/dx-2020-0046.
9
Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019.1420 例轻症至中症 2019 年冠状病毒病欧洲患者的临床和流行病学特征。
J Intern Med. 2020 Sep;288(3):335-344. doi: 10.1111/joim.13089. Epub 2020 Jun 17.
10
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区,5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.